Liposomal amphotericin B-the past.

Brüggemann, R J; Jensen, G M; Lass-Flörl, C

Brüggemann, R J; Jensen, G M; Lass-Flörl, C.

Affiliation

Brüggemann RJ; Department of Pharmacy, and Radboudumc Institute of Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Jensen GM; Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Center, Nijmegen, The Netherlands.
Lass-Flörl C; Pharmaceutical Development and Manufacturing, Gilead Sciences Inc., La Verne, CA, USA.

J Antimicrob Chemother ; 77(Suppl_2): ii3-ii10, 2022 11 25.

Article in En | MEDLINE | ID: mdl-36426673

Subject(s)

Candidiasis; Mycoses; Humans; Amphotericin B/adverse effects; Amphotericin B/pharmacokinetics; Antifungal Agents/adverse effects; Antifungal Agents/pharmacokinetics; Mycoses/drug therapy; Candidiasis/drug therapy; Liposomes/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Candidiasis / Mycoses Type of study: Guideline Limits: Humans Language: En Journal: J Antimicrob Chemother Year: 2022 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google